Diapharm makes changes to senior management team

Ralf Sibbing continues as General Manager while Martin Vortkamp leaves the company

Pharmaceutical service provider Diapharm, headquartered in Münster, Germany, is restructuring its senior management. Ralf Sibbing will continue as sole General Manager. Martin Vortkamp will leave the company by mutual agreement.

Diapharm founder Dr Stefan Sandner said there had been a difference in opinion regarding the strategic focus of Diapharm as a leading service provider and consulting firm for the consumer healthcare and pharmaceutical industry. Vortkamp joined Diapharm in 2009 and held a variety of positions at the company before being named Co-General Manager in 2012.

Founded in 1988, Diapharm supports and advises companies from the pharmaceutical and healthcare industry on regulatory, medical, pharmaceutical and quality assurance matters. The company employs more than 100 people at locations in Germany, Austria, the UK and China.

You may also like

Regulatory

Diapharm authorised to assist medical device registration in Switzerland

Procedural changes were made in May 2021 in relation to the marketing and distribution of medical devices in Switzerland
Regulatory

Diapharm becomes European Authorised Representative

Companies based outside the EU that want to market their products in it must appoint a representative. Diapharm has been certified as such for medical devices
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Subscribe now